SHR-2106 / Jiangsu Hengrui Pharma - LARVOL DELTA

A phase I clinical study of the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-2106, an anti-CD40 antibody, following single intravenous or subcutaneous administration in healthy participants. (PubMed, Eur J Pharmacol) - "SHR-2106 was well tolerated and achieved rapid and sustained CD40 engagement, supporting dose and route selection for Phase II studies."

Clinical • First-in-human • Journal • P1 data • PK/PD data • CD40LG

Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=52 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Enrolling by invitation ➔ Completed

Trial completion • Transplantation

Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=58 | Enrolling by invitation | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Transplantation

Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=58 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Transplantation